MediciBioㅣ메디치바이오

Mutant-Selective Oligonucleotide Drug

MediciBIO develops gene therapy for incurable genetic diseases through systemic infrastructure - genetic disease analysis, RNAi screening, efficacy evaluation, CMC study, and collaboration of clinical advisors.

Analysis of Genetic Diseases

MediciBIO primarily defines driver mutations of genetic diseases through genetic analysis.

Mutant-Selective OND Screening

MediciBIO screens and optimizes siRNA or ASOs (anti-sense oligonucleotides) for selection of candidates that discriminate mutant mRNAs over the corresponding wild-type mRNAs.

In vitro/in vivo Evaluation

Establishment of in vitro/in vivo genetic models via constitutive expression or gene-editing enables preclinical evaluation and prediction of clinical efficacy.

CMC for Gene Therapy Products

Experience in CMC study and IND filing of highly complex genetic drugs including oligonucleotides facilitates rapid clinical entry and drug development.

Mutant-selective Oligonucleotide Drug

MediciBIO develops gene therapy for incurable genetic diseases through systemic infrastructure-genetic disease analysis, OND screening, efficacy evaluation, CMC study, and collaboration of clinical advisors.